Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00962949 · ClinicalTrials.gov registry record · Phase 1

The Renin-Aldosterone Axis in Postural Tachycardia Syndrome

A Phase 1 study of Postural Orthostatic Tachycardia Syndrome (POTS), sponsored by Vanderbilt University Medical Center.

Completed
Registry status
Phase 1
Development phase
28
Enrollment target
1
Study location

NCT00962949: Completed Phase 1 study of Postural Orthostatic Tachycardia Syndrome (POTS), sponsored by Vanderbilt University Medical Center.

NCT00962949 is a Phase 1 study of Postural Orthostatic Tachycardia Syndrome (POTS) that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 28 participants, below the 103-participant average among 4 other Postural Orthostatic Tachycardia Syndrome (POTS) trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00962949, a Phase 1 study of Postural Orthostatic Tachycardia Syndrome (POTS), has completed, sponsored by Vanderbilt University Medical Center.

COMPLETED
Registry status
Phase 1
Development phase
28 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine the role of the renin-angiotensin-aldosterone in the pathophysiology of postural tachycardia syndrome, and to provide an insight about the disease process in this disorder.

Primary Outcome

Change in MAP from baseline to after 1h of infusion.

Interventions

  • DRUG Angiotensin II

Study Locations (1)

Tennessee

  • Vanderbilt University - Nashville

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2009-04
Est. Completion 2012-12
Phase Phase 1

What the finished NCT00962949 record still lists

NCT00962949 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 103-participant average among 4 other Postural Orthostatic Tachycardia Syndrome (POTS) trials with a reported enrollment target (73% lower).

The record links to 1 condition, with Postural Orthostatic Tachycardia Syndrome (POTS) appearing as the primary indexed condition, and to 1 intervention - of which Angiotensin II is the first listed.

NCT00962949 reports a single indexed study location in Tennessee.

Frequently Asked Questions

What is clinical trial NCT00962949 about?

NCT00962949 is a clinical study titled "The Renin-Aldosterone Axis in Postural Tachycardia Syndrome". The purpose of this study is to determine the role of the renin-angiotensin-aldosterone in the pathophysiology of postural tachycardia syndrome, and to provide an insight about the disease process in this disorder.

What is the current status of trial NCT00962949?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2009-04. Estimated completion is 2012-12.

What conditions does trial NCT00962949 study?

This clinical trial studies the following conditions: Postural Orthostatic Tachycardia Syndrome (POTS).

What interventions are being tested in trial NCT00962949?

The interventions under investigation include: Angiotensin II (DRUG).

Who is sponsoring clinical trial NCT00962949?

This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00962949 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Postural Orthostatic Tachycardia Syndrome (POTS)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03471117 · 28 participants · Phase 4

    Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients

  • NCT03523975 · 28 participants · Phase 1

    Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

  • NCT03608631 · 28 participants · Phase 1

    iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

  • NCT03810651 · 28 participants · Early Phase 1

    Pencil Beam Scanning in Patients With Renal Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00962949, the US trial registry maintained by the National Library of Medicine. NCT00962949 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.